Chouvet C, Vicard E, Frappart L, Falette N, Lefebvre M F, Saez S
Centre Leon Berard, Lyon, France.
J Steroid Biochem. 1988 Oct;31(4B):655-63. doi: 10.1016/0022-4731(88)90015-5.
The antiestrogenic activities of Tamoxifen have been well documented and this molecule has been successfully used in the treatment of hormone dependent breast cancer. In the present experiments we demonstrate that 4-hydroxy-Tamoxifen (OH-TAM) is able to reduce the growth of the BT-20 cell line which is devoid of estrogen and progesterone receptors. Various parameters have been investigated in growth studies under control conditions and in the presence of OH-TAM. Cell numerations, [3H]thymidine incorporation per cell or per microgram of DNA have shown that OH-TAM reduces the growth rate in proportion to its concentration from 10(-9) M to 10(-6) M. This activity is not reversed by estradiol addition. It is unaffected by the presence or the absence of Phenol Red in the medium. Analysis by flow cytometry suggests that it takes place before the S phase of the cycle. Examination of control and treated cells by Electron Microscopy shows no sign of toxicity. The growth inhibitory activity of OH-TAM on these cell lines appears therefore unrelated to its antiestrogenic properties.
他莫昔芬的抗雌激素活性已有充分记载,该分子已成功用于治疗激素依赖性乳腺癌。在本实验中,我们证明4-羟基他莫昔芬(OH-TAM)能够抑制BT-20细胞系的生长,该细胞系缺乏雌激素和孕激素受体。在对照条件下以及存在OH-TAM的情况下,我们对生长研究中的各种参数进行了研究。细胞计数、每细胞或每微克DNA的[3H]胸苷掺入量表明,OH-TAM以10(-9)M至10(-6)M的浓度比例降低生长速率。添加雌二醇不会逆转这种活性。培养基中有无酚红对其无影响。流式细胞术分析表明,这种作用发生在细胞周期的S期之前。通过电子显微镜检查对照细胞和处理过的细胞未发现毒性迹象。因此,OH-TAM对这些细胞系的生长抑制活性似乎与其抗雌激素特性无关。